Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| PBLSParabilis Medicines, Inc. | RA Capital Management, L.P. (Peter Kolchinsky / Rajeev M. Shah)10% Owner / Director | $6.92M | Added | |||
| 6 open-market transactions Jul 20–22 at weighted avg prices $27.13–$30.00/share. RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP purchased jointly; total beneficial ownership ~29.2M shares. Stock now $30.81 (+8.9% vs $28.29 blended avg buy price). No specific earnings catalyst identified; aggressive accumulation at rising prices. | ||||||
| CLBKColumbia Financial, Inc. | Thomas J. KemlyPresident & CEO | $531K | Added | |||
| Second-step mutual-to-stock conversion subscription at $10.00/share (Jul 20, 2026). 40,000 shares direct + 13,057 via 401(k). Stock now $10.94 (+9.4%). Part of 16-insider cluster filing on the same day; CLBK began Nasdaq trading Jul 21, 2026 after $1.7B capital raise and Northfield Bancorp acquisition close. | ||||||
| CLBKColumbia Financial, Inc. | Allyson Katz SchlesingerSEVP & Head of Consumer Banking | $500K | Added | |||
| Second-step conversion subscription at $10.00/share (Jul 20, 2026). 44,400 direct + 5,600 shares in second tranche. Stock now $10.94 (+9.4%). | ||||||
| CLBKColumbia Financial, Inc. | Steven M KleinSr. EVP & COO | $500K | Added | |||
| Second-step conversion subscription at $10.00/share (Jul 20, 2026). Stock now $10.94 (+9.4%). Post-transaction holdings: 711,570 direct shares. | ||||||
| HDSNHudson Technologies, Inc. | Hartree Partners, LP10% Owner | $393K | Added | |||
| 2 open-market purchases: 17,842 shares at $5.9892 (Jul 20) + 47,708 shares at $5.9894 (Jul 21). Post-transaction: 5,042,086 shares. No 10b5-1 plan indicated. Stock now $6.19 (+3.4% vs $5.989 blended avg buy). Refrigerant reclamation sector; 10% owner adding at multi-year lows. | ||||||
| CLBKColumbia Financial, Inc. | John KlimowichSEVP & Chief Risk Officer | $350K | Added | |||
| Second-step conversion subscription at $10.00/share (Jul 20, 2026). 5,000 direct + 30,000 via 401(k). Stock now $10.94 (+9.4%). | ||||||
| NMMNavios Maritime Partners L.P. | Angeliki FrangouCEO & Chairwoman of the Board | $253K | Added | |||
| 3 open-market purchases Jul 20–22 via Rule 10b5-1 plan (Raymar Investments S.A. / UBS Financial Services, plan adopted Dec 9, 2025): 1,167 shares @$72.95, 1,149 @$74.03, 1,121 @$74.07. Also a director/10% owner. Stock now $73.66 (-0.0% vs $73.68 avg). Automated plan reduces discretionary signal. | ||||||
| CLBKColumbia Financial, Inc. | Robert Van DykDirector | $250K | Added | |||
| Second-step conversion subscription at $10.00/share (Jul 20, 2026). Post-transaction: 322,013 direct shares. Stock now $10.94 (+9.4%). | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings. 8 qualifying buys (≥ $250K, transaction type P) totalling $9.7M.
Dominant theme — CLBK second-step conversion cluster. Columbia Financial (CLBK) completed its mutual-to-stock second-step conversion on July 20–21, 2026, raising $1.7B at $10/share and simultaneously closing a $580M acquisition of Northfield Bancorp. Five qualifying insiders — CEO, COO, and three senior EVPs — subscribed a combined $2.13M to conversion shares. These are subscription purchases (not open-market), but all are coded "P" in Form 4 and represent real cash commitments. CLBK is already trading at a ~9.4% premium to the $10.00 offering price just two trading sessions in.
PBLS — aggressive institutional accumulation in biotech. RA Capital Management (a specialist healthcare fund) accumulated 244,593 additional PBLS shares across six sessions at rising prices ($27.13 → $30.00), for nearly $6.9M. With ~29.2M shares post-buy, RA Capital holds a dominant stake in this recently-public biotech. The willingness to buy at the top of the range is a strong vote of confidence.
HDSN — 10% owner quietly adding. Hartree Partners bought 65,550 shares of Hudson Technologies at ~$5.99 on Jul 20–21. Hudson is a refrigerant reclamation company under pressure from pricing normalization; a large 10% holder continuing to build at current levels signals conviction in a near-term recovery.
NMM — 10b5-1 context. Frangou's NMM purchase was executed under a pre-scheduled Rule 10b5-1 plan adopted December 9, 2025. Carries less discretionary signal than the other filings — plan was set up months ago.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.